Research field (3):
Tumor diagnostics and therapeutics
, Tumor biology
, General surgery, pediatric surgery
Research theme for competitive and other funds (9):
2022 - 2025 乳癌におけるのAbscopal効果の検証と放射線療法効果モニタリングの開発
2017 - 2022 Clinical significance of ABCG2/BCRP quantified by fluorescence nanoparticle in breast cancer patients undergoing neoadjuvant chemotherapy
2016 - 2020 A cohort study in relation to lifestyle factors responsible for improvement of cancer patient survival and quality of life
2017 - 2019 Prediction for treatment in breast cancer using T cell and B cell repatoire analysis.
2015 - 2017 Quantitative evaluation of estrogen receptor and the validation for breast cancer by nano particle-based immunohistochemistry
2014 - 2017 Quantification of breast cancer microenvironment by three dimensional integration of micro bubble contrast ultrasound and MRI image
2013 - 2017 Basic construction for treatment effect prediction of molecular targeted drugs by quantitative estimation of HER family receptor based on highly sensitive nanoparticle imaging
2014 - 2016 Construction of the treatment algorithm for triple negative breast cancer
2010 - 2012 Elucidation of the biological properties of triple negative breast cancer and construction of a therapeutic strategy
Show all
Papers (168):
Shiori Fujisawa, Kiyoshi Takagi, Mio Yamaguchi-Tanaka, Ai Sato, Yasuhiro Miki, Minoru Miyashita, Hiroshi Tada, Takanori Ishida, Takashi Suzuki. Receptor for Hyaluronan Mediated Motility (RHAMM)/Hyaluronan Axis in Breast Cancer Chemoresistance. Cancers. 2024. 16. 21. 3600-3600
Asumi Yamazaki, Hiroshi Tada, Yuki Muroyama, Yuto Yamazaki, Minoru Miyashita, Narumi Harada-Shoji, Yohei Hamanaka, Akiko Ebata, Miku Sato, Tokiwa Motonari, et al. Surgical and irradiated case of early breast cancer in a patient with Ehlers-Danlos syndrome. Surgical case reports. 2024. 10. 1. 195-195
Shiori Fujisawa, Kiyoshi Takagi, Mio Yamaguchi-Tanaka, Ai Sato, Yasuhiro Miki, Minoru Miyashita, Hiroshi Tada, Takanori Ishida, Takashi Suzuki. Clinicopathological significance of hyaluronan and hyaluronidase 2 (HYAL2) in breast cancer. Pathology - Research and Practice. 2024. 155434-155434
Reina Taguchi, Mio Yamaguchi-Tanaka, Kiyoshi Takagi, Ai Sato, Yasuhiro Miki, Minoru Miyashita, Takashi Suzuki. Clinicopathological Significance and Prognostic Role of High Mobility Group Box 1 (HMGB1), Toll-Like Receptor (TLR) 2 and TLR4 in Breast Cancer. ACTA HISTOCHEMICA ET CYTOCHEMICA. 2024. 57. 2. 75-83
核外ERαの定量分析に基づくHR+/HER2乳癌の内分泌療法抵抗性の予測(Prediction of endocrine therapy resistance in HR+/HER2 breast cancer based on quantitative analysis of extranuclear ERα)
(日本癌学会総会記事 2019)